Evidence map›Paper›PMID 26395176›Full record

ArticleJournal of pathology and translational medicine2015

Parafibromin Staining Characteristics in Urothelial Carcinomas and Relationship with Prognostic Parameters.

Serap Karaarslan, Banu Yaman, Hakan Ozturk, Banu Sarsik Kumbaraci

Abstract read
In one paragraph

Article in Journal of pathology and translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. The roles of the tumor suppressor parafibromin in cancer.Frontiers in cell and developmental biology · 2022
    Review
  5. Article
  6. Article
  7. Significance of Parafibromin Expression in Laryngeal Squamous Cell Carcinomas.Journal of pathology and translational medicine · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Serap KaraarslanDepartment of Pathology, Sifa University Faculty of Medicine, Izmir, Turkey.
Banu YamanDepartment of Pathology, Ege University Faculty of Medicine, Izmir, Turkey.
Hakan OzturkDepartment of Urology, Sifa University Faculty of Medicine, Izmir, Turkey.
Banu Sarsik KumbaraciDepartment of Pathology, Ege University Faculty of Medicine, Izmir, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParafibromin is a recently defined tumor suppressor gene. The aim of our study was to determine the relationships of parafibromin expression in urothelial carcinomas (UCs) with prognostic parameters and to evaluate the use of parafibromin as a potential marker of UC.

methodsParafibromin expression was assessed in 49 UC specimens using immunohistochemistry. The correlations between parafibromin expression and clinical and pathologic parameters were investigated.

resultsOf the patients, 42 (85.7%) were male, and the mean age was 69.6 ± 8.2 years (range, 54 to 88 years). Morphologically, the UCs were divided into two groups: papillary (n = 27) and non-papillary (n = 22). There were seven low-grade (14.3%) and 42 high-grade (85.7%) tumors. Parafibromin was negative in 13 tumors (26.5%), partially positive in 19 tumors (38.8%), and positive in 17 tumors (34.7%). Parafibromin expression was more negative in UCs from upper urinary locations (n=17) and with muscularis propria invasion (n=28), which was statistically significant (p = .009 and p = .007, respectively). There was no statistically significant relationship between parafibromin expression and gender, age, tumor grade, survival, or disease-free survival.

conclusionsWe found that UC cases with parafibromin positivity had less of a tendency to show muscularis propria invasion and were more commonly located in the lower urinary system. These results need to be confirmed with studies based on larger case series.

Indexed as

Muscularis propriaNon-papillaryPapillaryParafibrominUrothelial carcinoma

Identifiers

PMID26395176
PMCPMC4579279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.